Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Core Insights - Entera Bio Ltd. and OPKO Health, Inc. announced positive topline pharmacokinetic/pharmacodynamic results from their collaboration on a proprietary long-acting oxyntomodulin (OXM) analog, aimed at developing the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders [1][2] Group 1: Collaboration and Research Progress - The collaboration has successfully completed in vivo proof-of-concept PK/PD studies in rodent and pig models, demonstrating significant systemic exposure and favorable pharmacokinetic profiles for oral OXM [2][3] - A glucose tolerance test in rats showed that oral OXM significantly reduced plasma glucose levels compared to placebo, indicating its potential efficacy [3][4] Group 2: Product Development and Market Potential - Entera is developing the first oral oxyntomodulin in tablet form, which could provide a non-injection alternative for obesity treatment, addressing a significant unmet medical need [6] - OPKO's previous studies indicated that weekly injections of pegylated OXM led to significant weight loss and improvements in metabolic markers among obese and diabetic patients, highlighting the therapeutic potential of OXM [5] Group 3: Company Profiles - Entera Bio is focused on developing oral peptide therapies for unmet medical needs, with a pipeline that includes five first-in-class oral peptide programs expected to enter clinical trials by 2025 [6] - OPKO Health is a multinational biopharmaceutical company aiming to establish leading positions in rapidly growing markets through its proprietary technologies and expertise in drug development [7]